40 Participants Needed

WAL0921 for Healthy Subjects

CO
Overseen ByClinical Operations Director
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Walden Biosciences

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new drug called WAL0921 in healthy people to see if it is safe and understand how it moves through and affects the body.

Will I have to stop taking my current medications?

The trial is for healthy individuals without current medical conditions, so participants likely should not be on any medications. The protocol does not specify, but it seems participants should not be taking regular medications.

What safety data exists for WAL0921 in healthy subjects?

There is general safety data from phase I studies involving healthy volunteers, which show that adverse events (unwanted effects from the treatment) can occur, but the frequency and seriousness vary. These studies help understand the safety of treatments like WAL0921, even if they were tested under different names or for other conditions.12345

Who Is on the Research Team?

AB

Andrew Blair, MD

Principal Investigator

Walden Biosciences, Inc.

Are You a Good Fit for This Trial?

This trial is for healthy adults between the ages of 18 and 65 with a BMI between 18 and 32 kg/m2. Participants should not have any known current or chronic medical conditions.

Inclusion Criteria

Healthy individuals without known current or chronic medical conditions in the opinion of the Investigator Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single intravenous infusion of WAL0921 or placebo

1 day

Follow-up

Participants are monitored for safety and effectiveness after treatment

64 days

What Are the Treatments Tested in This Trial?

Interventions

  • Placebo
  • WAL0921
Trial Overview The study is testing WAL0921, a new drug, against a placebo (a substance with no active drug). It's randomized and double-blind, meaning neither the researchers nor participants know who gets the real drug or placebo.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: WAL0921Experimental Treatment1 Intervention
Single intravenous infusion of investigational drug WAL0921
Group II: PlaceboPlacebo Group1 Intervention
Single intravenous infusion of normal saline

Find a Clinic Near You

Who Is Running the Clinical Trial?

Walden Biosciences

Lead Sponsor

Trials
2
Recruited
140+

Published Research Related to This Trial

In a meta-analysis of 11,028 healthy participants across 394 non-oncology phase I studies, 63.7% experienced adverse events, but 85% of these were classified as mild, indicating a relatively safe profile for the study drugs.
Only 0.31% of participants experienced serious adverse events, with no deaths or life-threatening incidents reported, suggesting that while adverse events are common, they are mostly not severe.
Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies.Emanuel, EJ., Bedarida, G., Macci, K., et al.[2018]
A new standardized strategy for reporting adverse events (AEs) and serious adverse events (SAEs) in substance use disorder (SUD) clinical trials was developed, which aims to reduce the reporting burden while maintaining safety monitoring.
In a review of 17 SUD trials involving 6737 participants, the new strategy showed a significant reduction in irrelevant safety event reporting, leading to a more consistent safety assessment system tailored to the risks associated with specific trial interventions.
Strategies for safety reporting in substance abuse trials.Lindblad, R., Campanella, M., Styers, D., et al.[2013]
In a comprehensive review of 54 phase-I studies involving 1015 healthy volunteers over 10 years, the overall incidence of adverse events was found to be 12.8%, with a higher rate for active drugs (13.7%) compared to placebo (7.9%).
Most adverse events were minor, with only 3% classified as severe, and no deaths or life-threatening events reported, highlighting that while adverse events are common in phase-I trials, they are typically not serious.
Adverse events in phase-I studies: a report in 1015 healthy volunteers.Sibille, M., Deigat, N., Janin, A., et al.[2019]

Citations

Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies. [2018]
Strategies for safety reporting in substance abuse trials. [2013]
Adverse events in phase-I studies: a report in 1015 healthy volunteers. [2019]
ADVERPred-Web Service for Prediction of Adverse Effects of Drugs. [2018]
A curated and standardized adverse drug event resource to accelerate drug safety research. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security